相关实验视频

Updated: Jun 19, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

新型Gd-DTPA-酸用于向乳腺瘤磁共振成像

Nooshin Reisi Zargari¹, Fatemeh Ebrahimi², Mehdi Akhlaghi³

¹University Campus II, University of Guilan, Rasht, Iran.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

|July 26, 2024

概括

一种新的MRI对比剂,Gd-DTPA-VGB3,针对VEGFRs进行增强的乳腺癌成像. 与标准的马格尼维斯特相比,这种药物显示出改善的瘤可视化和积累,有助于早期诊断.

科学领域:

生物医学成像技术生物医学成像技术
纳米技术纳米技术
在瘤学瘤学.

背景情况:

乳腺癌的诊断依赖于早期检测以获得有效的治疗.
传统的MRI对比剂,如马格尼维斯特在瘤特异性的局限性.
针对特定的生物标志物,如血管内皮生长因子受体 (VEGFRs),可以改善成像.

研究的目的:

开发和评估一种新的MRI对比剂Gd-DTPA-VGB3,用于增强乳腺瘤检测.
评估Gd-DTPA-VGB3针对VEGFR1和VEGFR2的特异性和有效性.
在临床前模型中,比较Gd-DTPA-VGB3与传统Magnevist的性能.

主要方法:

使用Fmoc固相合成和DTPA合合成Gd-DTPA-VGB3.
在体外评估通过位移结合试验对VEGFR1/2的结合亲和力.
对正常和癌细胞系 (MCF-10和4T1) 的细胞毒性评估.
在4T1瘤携带小鼠体内MRI研究以评估对比度增强和积累.

主要成果:

Gd-DTPA-VGB3 已证明与 VEGFR1/2.2 的特定结合.
该药物对正常细胞具有较低的细胞毒性,并抑制了癌细胞的增殖.
Gd-DTPA-VGB3实现了比Magnevist.com高出2.8倍的对比度和噪声比率 (CNR).
在治疗小鼠的瘤中观察到增强的积累和信号强度.

结论:

Gd-DTPA-VGB3是一种有前途的新型MRI对比剂,具有特定的VEGFR向.
该药物在临床前乳腺癌模型中显著改善了MRI对比度和瘤可视化.
Gd-DTPA-VGB3有可能通过增强的MRI来推进乳腺癌诊断.

关键词:

乳腺癌乳腺癌乳腺癌磁力共振成像对比度增强器这是一种类.瘤向向的目标在VEGFR1/2的基础上.

更多相关视频

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging

Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging

Published on: December 15, 2014

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Magnetic Resonance Imaging

Magnetic Resonance Imaging

Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique based on a phenomenon of nuclear physics discovered in the 1930s, in which matter exposed to magnetic fields and radio waves was found to emit radio signals. In 1970, a physician and researcher named Raymond Damadian noticed that malignant (cancerous) tissue gave off different signals than normal body tissue. He applied for a patent for the first MRI scanning device in clinical use by the early 1980s. The early MRI...